智通财经APP讯，金活医药集团(01110)发布截至2024年12月31日止年度业绩，该集团取得收益人民币10.61亿元(单位下同)，同比减少1.63%;公司拥有人应占溢利4155.7万元，同比增加9.08%;每股盈利7.22分，拟派发末期股息每股 3.17港仙。
受本集团产品结构战略性调整及行业宏观环境变化影响，于回顾年度内，来自药品分销分部销售额录得销售额约7.5亿元，按年增长 2.0%，品牌影响力持续提升。其中，本集团主力代理药品京都念慈庵川贝枇杷膏表现符合预期，发展良好。凭藉其卓越的疗效品质与良好的产品口碑，结合精准的营销推广策略，京都念慈庵川贝枇杷膏成功拓展年轻群体市场。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.